Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !
Ga offline met de app Player FM !
Amplia Therapeutics: Advancing Pancreatic Cancer Treatment
MP3•Thuis aflevering
Manage episode 435437094 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
624 afleveringen
MP3•Thuis aflevering
Manage episode 435437094 series 2891889
Inhoud geleverd door Proactive Investors. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Proactive Investors of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
624 afleveringen
Minden epizód
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.